This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share.

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

Tremfya (guselkumab ... The antibody is already approved to treat plaque psoriasis, psoriatic arthritis and, since last September, in ulcerative colitis, achieving sales of almost $3.7 billion ...

Presentation Operator Good morning, and welcome to Johnson Johnson's First Quarter 2025 Earnings Conference Call. [Operator ...

Discover 5 insights about psoriatic arthritis from rheumatology experts, including pain management strategies, treatment ...

Visible signs of psoriatic arthritis appear months and even years before a person develops the full-blown inflammatory joint ...

A rheumatologist discusses how her understanding of chronic pain in PsA has evolved—and how it affects her approach to ...

Medically reviewed by Stella Bard, MD Psoriatic arthritis (PsA) is a chronic (long-term) condition that includes symptoms of ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...